Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Brings Lawton In-House As VP-Reg Affairs/Counsel: PDUFA III Looms

Executive Summary

Biotechnology Industry Organization VP-Regulatory Affairs Stephan Lawton will focus on the reauthorization of the Prescription Drug User Fee Act upon joining the association on Jan. 1, 2001.
Advertisement

Related Content

BIO Seeking Regulatory Affairs Head, Gets Friendly Face In House Committee
BIO Seeking Regulatory Affairs Head, Gets Friendly Face In House Committee
BIO VP-Health Policy Cohen Joins From HIAA To Handle Medicare Rx Policy
BIO VP-Health Policy Cohen Joins From HIAA To Handle Medicare Rx Policy
BIO VP-Government Relations Rawls Has Been Frist Chief Of Staff For 4 Years
BIO VP-Government Relations Rawls Has Been Frist Chief Of Staff For 4 Years
BIO
BIO
User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal
BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics
Advertisement
UsernamePublicRestriction

Register

PS036403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel